Is the Mayne Pharma Group Ltd share price in the buy zone after today's news?

The Mayne Pharma Group Ltd (ASX:MYX) share price has tumbled lower despite a positive announcement today. Here's what you need to know…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Unfortunately for its shareholders this morning the Mayne Pharma Group Ltd (ASX: MYX) share price has tumbled lower despite the release of a positive announcement.

In early trade the pharmaceutical company's shares are down almost 2% to $1.02.

What was the announcement?

This morning Mayne Pharma announced that it had gained approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for doxycycline hyclate immediate release tablets.

As a result the company has immediately commenced a commercial launch to customers in the United States.

Doxycycline hyclate immediate release tablets are generic versions of Acticlate tablets. Acticlate is a tetracycline-class antibacterial indicated for the treatment of a number of infections, including adjunctive therapy in severe acne.

According to the release, annual sales of the Acticlate in the United States were approximately US$250 million for the twelve months to April 2017.

Should you invest?

Whilst the sales from this drug are unlikely to move the needle significantly in the future, it is just one of a number of drugs that Mayne Pharma has in its pipeline.

Management estimates that it markets more than 50 products and has a growing pipeline of more than 40 products targeting markets with sales of greater than US$7 billion.

Clearly there is significant growth potential from these drugs if things stay the same way. However, with President Trump intent on cutting the price of generic drugs, it is difficult to gauge the impact this will have on its future sales.

Whilst I believe Mayne Pharma is likely to be a great long-term buy and hold investment, I'm not convinced that its share price has found its bottom yet. Especially with short interest continuing to rise.

So for this reason I would suggest investors hold off an investment for the time being and focus on other healthcare shares like CSL Limited (ASX: CSL) and Ramsay Health Care Limited (ASX: RHC).

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »